Logo-npj
Submitted: 19 May 2018
Accepted: 27 Aug 2017
ePublished: 19 Sep 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2018;7(1): 10-17.
doi: 10.15171/npj.2018.04
  Abstract View: 11365
  PDF Download: 5549

Review

Efficacy and adverse effects of cidofovir for treatment of BK virus infection in kidney transplant recipients

Supavit Chesdacha 1,2, Charat Thongprayoon 3, Jackrapong Bruminhent 2, Wisit Cheungpasitporn 4,5*

1 Department of Medicine, University of Minnesota, Minnesota, USA
2 Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
3 Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA
4 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
5 Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Mississippi, USA
*Corresponding Author: *Corresponding author: Wisit Cheungpasitporn, MD; Email: , Email: wcheungpasitporn@gmail.com

Abstract

Kidney transplant provides patients with end-stage kidney disease a clear survival benefit compared to patients who remain on dialysis. Immunosuppressive therapy is crucial for maintaining graft survival. However, high level of suppression can increase the susceptibility for BK virus reactivation following transplantation, leading to BK virus-associated nephropathy (BK-VAN) and allograft loss. Its clinical presentations are often asymptomatic or solely rising of serum creatinine. While reduction of immunosuppression remains the mainstay treatment of BK viremia/nephropathy, there have been many proposed adjuvant therapy such as antiviral agents, fluoroquinolone, immunoglobulin, and immunotherapy. Cidofovir is one of the adjuvant therapies that have been studied in many case series and cohort studies with unclear data on benefit-risk assessment. This review aims to present the current literature on the efficacy, potential adverse effects and cost-effectiveness of cidofovir treatment for BK viremia/nephropathy. 

Implication for health policy/practice/research/medical education:

This review aims to present the evidence of benefit-risk assessment of cidofovir treatment for BK virus infection in kidney transplant recipients. In this review, we discussed the efficacy and adverse side effects, which help physicians in the clinical judgment for the use of cidofovir addition to a reduction of immunosuppressant. Moreover, this review also provides brief review of current view in BK virus burden, clinical manifestation, diagnosis and other treatment methods which can be beneficial in clinical practice and future research.

Please cite this paper as: Chesdachai S, Thongprayoon C, Bruminhent J, Cheungpasitporn W. Efficacy and adverse effects of cidofovir for treatment of BK virus infection in kidney transplant recipients. J Nephropharmacol. 2018;7(1):10-17. DOI: 10.15171/ npj.2018.04. 

 

 

 

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 11366

Your browser does not support the canvas element.


PDF Download: 5549

Your browser does not support the canvas element.